Geron, a medicine company, just shared its financial results for the last three months of 2024. They sell a new drug called Rytelo to help people with a blood disease called MDS. It's been approved in the US and is soon to be approved in Europe.
- Rytelo sales reached $47.5 million in the last quarter of 2024.
- Sales have been flat recently, but the company is working on boosting them.
- Geron is also testing another drug, imetelstat, for a different blood disease called myelofibrosis.
| Item | Number |
|---|---|
| Rytelo Q4 2024 Sales (US$) | $47.5 million |
| Geron's cash on hand (US$) | $503 million |
| Estimated US Rytelo addressable market in 2025 | 15,400 patients |
| Imetelstat Phase 3 trial interim results expected | Second half of 2026 |
